Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Leukemia|August 14, 2024
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligandsErika Tissino, Annalisa Gaglio, Antonella Nicolò, et al.
Cancer|December 28, 2023
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapyFrancesca Palandri, Giuseppe A Palumbo, Giulia Benevolo, et al.
Cancers|October 28, 2023
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with MyelofibrosisFrancesca Palandri, Giuseppe A Palumbo, Massimiliano Bonifacio, et al.
Cancer|December 21, 2019
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosisFrancesca Palandri, Massimo Breccia, Massimiliano Bonifacio, et al.
Cancer|July 30, 2024
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World StudyFrancesca Palandri, Elena M Elli, Erika Morsia, et al.
Seminars in Hematology|December 4, 2018
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎Francesca Palandri, Giuseppe A Palumbo, Alessandra Iurlo, et al.
British Journal of Haematology|November 22, 2020
Second primary malignancy in myelofibrosis patients treated with ruxolitinibNicola Polverelli, Elena M Elli, Elisabetta Abruzzese, et al.
Blood|March 5, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosisBarbara Mora, Francesca Palandri, Paola Guglielmelli, et al.
Cancer|March 18, 2023
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcomeFrancesca Palandri, Massimo Breccia, Camilla Mazzoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2023
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)Esther Natalie Oliva, Marta Riva, Pasquale Niscola, et al.
Pageof 12